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Abstract
Polymer based microparticles are increasingly becoming of interest for a variety of 
applications including drug delivery.  Recently poly(glycerol adipate) (PGA) and
poly(glycol adipate-co--pentadecalactone) have shown promise for delivery of 
dexamethasone phosphate and ibuprofen.  In this paper the copolyester poly(glycol 
adipate-co--pentadecalactone) was evaluated as a colloidal delivery system for 
encapsulated therapeutic proteins. Enzyme containing microparticles were prepared 
via the double water-in-oil-in-water (w/o/w) emulsion-solvent evaporation 
methodology.  -chymotrypsin was used as a model proteolytic enzyme and its 
transfer was monitored during the emulsification process, in addition to in vitro
release from formed particles. On average 22.1g protein per 1mg polymer was 
encapsulated, although gradual loss of activity of the protein, once released, was 
recorded. The work presented shows the potential of this polyester as a delivery 
system for enzymes via microparticles, with improvements to the system achievable 
via polymer and process optimisation.  The pendant hydroxyl groups on the polymer 
backbone provide future capacity for tailored alteration of the physical and chemical
properties of the polymer, in addition to covalent attachment of various compounds.
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Introduction
For the controlled delivery of various synthetic drugs and biomacromolecules a range 
of natural and artificial vehicles have been used. Liposomes (Sharma and 
Straubinger, 1994), micelles (Onyuksel et al., 1994), polysaccharides (Sharma et al., 
1995) and virus vectors (Schreier, 1994) all provide media for administration of
drugs. Additionally, micro/nanoparticles prepared from synthetic biodegradable 
polymers have also been employed (Crotts and Park, 1995; Davis et al., 1996; Sinha 
et al., 2004). Amongst the commonly used polymers for colloidal drug delivery 
approved for human use are poly(lactic acid) (Guiziou et al., 1996), poly(lactic-co-
glycolic acid) (Aguiar et al., 2004; Bilati et al., 2005) and poly(-caprolactone) (Kim
et al., 2005; Le Ray et al., 2003). There is also a growing list of novel synthetic 
biodegradable polymers that are being investigated for their potential in drug delivery 
systems, including polycarbonates, polyanhydrides, polymalic acid, 
polyphosphazenes, polyaminoacids (Davis et al., 1996), polyesters (Breitenbach et 
al., 2000; De Jesús et al., 2002) and poly-N-isopropylacrylamide and other responsive 
polymers (Alexander and Shakesheff, 2006).
Microparticles are of particular interest in drug administration as they provide a 
useful means of controlling drug delivery and release, in addition to being cheaper, 
easier to produce, more stable and highly manipulative in their physical 
characteristics, compared to the other formulations available. The incorporation of 
drugs into these systems can be achieved via encapsulation during particle formation. 
There is an array of particle preparation methodologies available using preformed 
polymers offering the choice of colloidal systems with different physical and 
chemical properties. The most commonly used particle preparation procedure 
enabling drug encapsulation is emulsion-solvent evaporation (Obeidat and Price, 
2003; Ogawa et al., 1988; Watts et al., 1990). This methodology has been applied to 
a diverse range of lipophilic drugs (Juni et al., 1985; Kim et al., 2005; Ruan and Feng, 
2003), however as such is not suitable for the encapsulation of hydrophilic drugs and 
biomolecules (Jalil and Nixon, 1990). Modifications to the emulsion-solvent 
evaporation technique have enabled successful entrapment and subsequent release of 
proteins and other hydrophilic compounds (Aguiar et al., 2004; Crotts and Park, 1995; 
Gaspar et al., 1998; Song et al., 1997; Zhang and Zhu, 2004). The multiple emulsion-
solvent evaporation methodology (Ogawa et al., 1988) involves preparing an internal 
water-in-oil (w1/o) emulsion, where the inner aqueous phase contains the chosen 
hydrophilic active and the oil phase the selected polymer and appropriate surfactant. 
This emulsion is further emulsified with a continuous water phase containing an 
appropriate stabiliser.  The thus formed water-in-oil-in-water (w1/o/w2) emulsion is 
mixed until the solvent evaporates and solid particles are formed. Such a system 
should allow for encapsulation of both hydrophilic and lipophilic molecules within 
the one colloidal system (Perez et al., 2000).  Adaptations to this methodology have
allowed for a diverse range of hydrophilic compounds to be encapsulated.
The multiple emulsion system for particle preparation is reliant upon a number of 
factors: amount and chemical/physical nature of the polymer, characteristics of the 
stabilisers, ratio and volumes of the phases, time and mixing speed of the different 
emulsifications, solvent choice, etc. With the solvent-evaporation particle preparation 
procedure the purpose of the surfactant is to stabilise the formed emulsion for a short 
time, while the solvent evaporates, thus preventing coalescence and aggregation of the 
droplets within the emulsion. The choice of stabiliser very much depends on the type 
of emulsion to be stabilised. The effects of surfactants are not limited to the 
preparation procedure of the particles, but also have an influence on the 
characteristics of the particles and hence release of active (Graves et al., 2005). 
The purpose of entrapment of the hydrophilic drugs or biomacromolecules is to 
obtain sustained release of the active over a period of time.  The release mechanism of 
the entrapped active molecules depends on their location within the particles. 
Desorption from the particle surface, diffusion through the polymer matrix, erosion of 
the polymer matrix or combinations of these are possible. The release profile of a 
given compound from a microparticle is governed by many parameters, including the 
nature of the polymer used, conditions of particle preparation, physical properties of 
the particles and the release environment. The particle surface morphology has also 
been shown to affect the release patterns (Le Ray et al., 2003). In principle, it should 
be possible to manipulate the release profiles of any colloidal drug delivery system to 
match the needs of the application.
The main properties that make colloidal systems good for drug delivery are the 
biocompatible (non-toxic) nature of the polymer based system, adequate 
biodegradation rates to enable the controlled release of the accompanying active 
molecule and suitability for the targeted therapeutic levels, in addition to drug 
incorporation amounts. Poly(glycol adipate) offers backbone functionality via 
pendant hydroxyl groups, which provide future potential for alteration of its physical 
and chemical properties, in addition to covalent attachment of various compounds. 
The possibility of tailoring the polymer chemistry expands its potential application in 
controlled delivery of a variety of molecules, compared to the commonly used 
polymers. Previous work on these and similar materials has focused on optimisation 
of nanoparticulate delivery systems for hydrophilic dextramethasone phosphate
(Kallinteri et al., 2005) and hydrophobic ibuprofen (Thompson et al., 2006; 
Thompson et al., 2007). This work explores the potential of poly(glycol adipate-co-
-pentadecalactone) in colloidal delivery systems affording sustainable release of an
encapsulated therapeutic protein.
Materials and methods
Materials
Glycerol, -pentadecalactone, Novozyme 435 (a lipase from Candida antartica
immobilised on a macroporous acrylic resin), -chymotrypsin (type II from bovine 
pancreas), Aerosol OT (dioctyl sodium sulfosuccinate), poly(vinyl alcohol) (PVA, 9-
10kMw, 80%, Sigma), azocasein, 4-methylumbelliferyl-p(N,N,N-
trimethylammonium) cinnamate (MUTMAC) and sodium orthoborate were all 
obtained from Sigma-Aldrich Chemicals (UK).  Dichloromethane, trichloroacetic acid 
(TCA), sodium hydroxide, N-[2-hydroxyethyl] piperazine-N’-[2-ethanesulfonic acid] 
(HEPES) and tetrahydrofuran (THF) were purchased from BDH (UK) whereas, 
phosphate buffered saline tablets at pH7.4 were obtained from Oxoid (UK).  Divinyl 
adipate was obtained for Fluorochem (UK).
Polymer synthesis
The copolymer poly(glycol adipate-co--pentadecalactone) was synthesised via an 
enzyme catalysed procedure adapted from Thompson et al. (2006).  Briefly, 0.05mol 
of glycerol, divinyl adipate and -pentadecalactone were added to a 250mL two-
necked round bottom flask followed by 15mL of tetrahydrofuran.  This was allowed 
to equilibrate to 50oC in a water bath, followed by the addition of 2.5% (w/v) of 
Novozyme 435 washed down with a further 5mL THF. An open top condenser was 
fitted to the flask. Stirring commenced at 2000rpm (setting 6 on the Heidolph RZR1 
stirrer) using a Teflon shaft and paddle and the reaction was allowed to proceed for 
24h. The resulting waxy liquid was further processed and analysed as outlined 
previously by Thompson et al. (2006) obtaining a white powder stored at room 
temperature. The polymer was characterised by GPC and NMR. The GPC system 
(Viscotek TDA Model 300 ran by OmniSEC3 operating software) was pre-calibrated 
with polystyrene standards (EasiCal A and B, Polymer Laboratories).
Particle preparation
For effective encapsulation of the model enzyme -chymotrypsin a multiple 
emulsion-solvent evaporation technique was employed (Ogawa et al., 1988). The
copolymer poly(glycerol adipate-co--pentadecalactone) was dissolved in 
dichloromethane.  The surfactant, chosen to stabilise the first water-in-oil (w/o) 
emulsion, was an ion-pairing anionic surfactant, Aerosol OT. It was dissolved in the 
oil phase with the polymer at a sub-critical micellial concentration of 2mM (Huibers
et al., 1997). 
The multiple emulsions were prepared as follows. A 1% (v/v) -chymotrypsin 
stock solution (100mg mL-1 made up in phosphate buffered saline at pH7.4) was 
added drop-wise to a homogenising solution of polymer (30mg mL-1) and Aerosol OT 
(2mM) in dichloromethane (15mL). The Polytron probe homogeniser (PT2100, 
11000rpm for 1min) was used to emulsify this water-in-oil emulsion. This configured 
the ‘first emulsion’, a water-in-oil system.  This was then gradually added to a mixing 
1% (w/v) PVA solution (135mL in a 200mL glass beaker) to form the water-in-oil-in-
water (w/o/w) multiple emulsion. The emulsion was left to mix with the Silverson L4 
RT mixer at 1000rpm for the required time to allow for dichloromethane evaporation.
Single emulsion particles were prepared as controls. Here the oil phase (15mL) 
containing the polymer (30mg mL-1) and Aerosol OT (2mM) was emulsified with the 
1% (w/v) PVA aqueous solution containing 150mg -chymotrypsin, using the 
Silverson L4 RT mixer at 1000rpm for the required time period. 
The particles obtained were collected by ultracentrifugation (rotor Ti70, Beckman 
L80 ultracentrifuge) at 30,000g for 15min.  The supernatants were labelled as ‘wash 
1’ samples and retained for further analysis. Each pellet was re-suspended in 20mL
deionised water to further remove residual PVA, and centrifuged as before, at 30,000g 
for 15min. These supernatants were collected as ‘wash 2’ samples. The particle-
containing pellets were re-suspended in 1.5mL deionised water, deep-frozen at -80oC 
prior to being freeze dried (Edwards Freeze Drier Super Modulyo).
The particles were visualised by scanning electron microscopy (JSM Jeol 840 
Scanning Electron Microscope). The 13mm aluminium stubs were layered with a 
carbon tab and 10-20L of particle suspension in water was deposited on the surface 
and air dried. An atomic layer of gold was deposited onto the particle containing 
stubs using the Polaron E 5000 Gold Sputter Coater.  Images were taken using the 
Rontech Image Capture System.
Partitioning of chymotrypsin from the emulsion
Single and multiple emulsions were prepared as described above.  Samples (1mL) of 
the emulsion formed were taken at timed intervals and the phases separated by 
centrifugation (2min at 13500rpm, MiniSpin Eppendorf). Initially there were two 
liquid phases (aqueous and polymer-containing oil) and the clear upper aqueous phase 
was retained at 4oC for further analysis.  As the dichloromethane evaporated, upon 
2.5h, solid polymer pellets were obtained and the aqueous supernatants collected and 
stored at 4oC. All the aqueous phases were subsequently assessed for protein content 
by measuring UV absorbance at 282nm, see below. 
Release of chymotrypsin from optimised particles
Three batches of particles were made via the double emulsion solvent evaporation 
technique as described above.  The particles were collected after 3h allowing 
sufficient time for the solvent to evaporate.  As controls, particles were prepared via 
the single emulsion solvent evaporation procedure, as described previously. They 
were collected after 3h mixing, processed and freeze dried as for the double emulsion 
particles.
Into clean dry 2mL microtubes, 10mg of freeze-dried particles was deposited.  To 
each one of these, 1mL of phosphate buffered saline pH7.4 at 37oC was added.  The 
microtubes were then incubated at 37oC in the orbital shaker set at 100rpm (InnovaTM
4340, New Brunswick Scientific).  To observe the release of enzyme from the 
particles sacrificial sampling was employed.  The samples were removed at increasing 
time points and centrifuged (5min at 13500 rpm, MiniSpin, Eppendorf) to collect 
particles. The supernatants obtained were collected and stored at 4oC for further 
analyses. The protein contents of the collected supernatants were determined using 
the assays described below.
Methods for assessing protein content and activity
The washes collected (wash 1 and 2) and supernatants obtained throughout the release 
studies were analysed for protein content and activity using the following methods:
Azocasein assay.  The proteolytic activity of chymotrypsin following incorporation 
and subsequent release from particles was determined using a chromogenic based 
technique – the azocasein assay (Charney and Tomarelli, 1947). 
The procedure was modified from the literature (Brock et al., 1982).  To 200L of 
10mg mL-1 azocasein, made in 25mM HEPES buffer (N-[2-Hydroxyethyl] 
piperazine-N’-[2-ethanesulfonic acid]), 50L sample, standard or blank were 
incubated overnight (16h) at 37oC.  The reaction was stopped by addition of 750L of 
0.3M trichloroacetic acid to precipitate the undigested protein-chromophore 
conjugate.  The samples were centrifuged (5min at 13,500 rpm, MiniSpin, Eppendorf) 
to remove the precipitate.  To 200L of the supernatant formed, 100L of 0.5M 
sodium hydroxide was added to intensify the orange colour formed.  Blank samples 
were made using deionised water to determine the amount of released azo-dye from 
the substrate non-enzymatically.  Absorbance was read at 415nm wavelength and 
compared to reagent blank samples using a multiwell spectrophotometer (Benchmark 
Microplate Reader, Biorad).  Three replicas of each sample were obtained and 
processed. 
UV absorbance.  To determine the total protein content present in the samples, their 
absorbance was measured at the optimum wavelength determined for chymotrypsin, 
282nm (UV/VIS spectrometer Lambda 40, Perkin Elmer, run via the UV WinLab 
version 2.80.03 software). The Plastibrand UV cuvettes (Fisher) were used. 
MUTMAC assay.  The chymotrypsin active site titration method described by (Gabel, 
1974) was used to assess residual active chymotrypsin in the samples. A 0.2mM 
solution of the fluorogenic compound 4-methylumbelliferyl-p(N,N,N-
trimethylammonium) cinnamate (MUTMAC) was prepared as the enzyme substrate. 
The reactions were set up in black 96 fluorescent plates (SLS) as follows.  To 200L 
sodium orthoborate buffer (0.1M at pH7.5), 50L MUTMAC solution was added 
together with 50L sample/standard/blank. These were mixed thoroughly prior to 
excitation at 360nm and measuring emission at 450nm. Measurements were taken on 
the fluorescence spectrophotometer, Varian Cary Eclipse, operated via the Cary 
Eclipse Advanced Reads Application version 1.1 (132) software.
Results and discussion
The focus of the work presented here was to evaluate the potential of the described 
polyester as a colloidal vehicle for protein delivery.  Throughout the development of 
the enzyme-containing colloidal systems, -chymotrypsin was chosen as the model 
enzyme, as it is commercially readily available with high units of activity.  Much 
work has been done on the chymotrypsins (Bender and Killheffer, 1973), thus a 
literature-based background knowledge of this enzyme and the economic advantages 
made it a feasible candidate for development of the delivery system. Additionally, 
investigations of the encapsulation of chymotrypsin into poly(D,L-lactic-co-glycolic 
acid) (PLGA) microspheres have previously been reported (Perez-Rodriguez et al., 
2003), however most of the literature focuses on other proteins including lysozyme 
(Jiang et al., 2002), bovine serum albumin (Panyam et al., 2003), asparaginase 
(Gaspar et al., 1998), etc. Here the encapsulation and activity of -chymotrypsin 
were monitored during the emulsification process and upon in vitro release from the 
poly(glycol adipate-co--pentadecalactone) based delivery system.
Polymer synthesis
The enzyme catalysed poly(glycol adipate-co--pentadecalactone) had a molecular 
weight of 30kDa compared to polystyrene standards.  Integration patterns of the 1H 
NMR demonstrated a 1:1:1 ratio of the three monomers used and the random nature 
of the polymer was confirmed by 13C NMR (Thompson et al., 2006).
Partitioning of chymotrypsin from double emulsion
To encapsulate chymotrypsin within the polymer colloidal system, a water-in-oil-in-
water multiple emulsion system was employed.  Here the enzyme was dissolved in the 
inner water phase and this was emulsified, initially within the polymer-containing oil 
phase, followed by a second outer aqueous phase. Diffusion of the chymotrypsin 
from the internal water section through the oil phase into the outer continuous water 
phase affects the encapsulation efficiency.  To assess this ‘movement’ of 
chymotrypsin during the particle formation process, its concentration in the outer 
aqueous phase was monitored over a period of time.  Initially the chymotrypsin 
diffused through the liquid oil phase containing the polymer. Upon solvent 
evaporation the enzyme continued to diffuse through the solid polymer particles into 
the surrounding aqueous phase. Whether this partitioning is due to micellar transport 
through the oil phase supported by the surfactants present, formation of hydrophilic 
channels or any other route, remains unclear.
Once the multiple emulsion was formed, samples were taken at regular time 
intervals and the oil and aqueous phases separated by centrifugation.  The protein 
content in the aqueous phase was measured using the UV assay (figure 1). A steady 
increase in chymotrypsin concentration was observed over time, changing from 
0.893(±0.060)mg mL-1 at 0min to 1.152(±0.037)mg mL-1 at 7h.  Once the solvent 
evaporated, upon 2.5h mixing, the enzyme continued to be released from the particles 
formed into the outer aqueous environment at a similar rate.
In the single emulsion control systems the protein concentration showed no 
significant change in concentration over the time period monitored, see figure 1.
[Insert FIGURE 1 about here]
From these observations it was concluded that the most convenient length of time 
for particle formation, under the given conditions, was 3h. This time allowed for 
evaporation of the solvent leading to solid polymer colloidal particles, yet minimised 
the subsequent loss of chymotrypsin.
Release of -chymotrypsin from optimised particles
Once the particle preparation time was optimised at 3h, three separate batches of 
multiple emulsion particles were prepared containing -chymotrypsin and one via the 
single emulsion procedure.  Figure 2 shows SEM images of particles prepared via this
multiple emulsion-solvent evaporation procedure. They ranged in size from 2m to 
12m and had a furrowed surface morphology.  These particles were used to observe 
the release of the enzyme.  The total protein present in the wash samples, collected
during particle preparation, is shown in table 1. High levels of PVA in the samples 
were considered to cause overestimation protein measurements using the UV and 
azocasein assays (unpublished observations).
[Insert FIGURE 2 about here]
From the results obtained it was observed that on average 10mg of chymotrypsin 
was encapsulated within the particles from the 3 batches, see table 1. The percentage 
encapsulation efficiencies for the 3 batches (D1 to D3) were calculated as the 
percentage of total protein not washed out during particle preparation, equation (1).
The enzyme load was defined as the amount of enzyme per unit polymer weight and 
the equation used is given below, equation (2).
            
_ _ _ ( )
. (%) 100
_ _ ( )
Protein not washed out mg
Encap Efficiency x
Protein amount added mg
               (1)
              100
)(__
)(__
(%)_ x
mgamountpolymerTotal
mgamountenzymeTotal
LoadEnzyme                     (2)
[Insert TABLE 1 about here]
Therefore the encapsulation efficiency calculated was, on average, 6.63(±3.55)% 
for the three batches made.  Whereas, the enzyme load was estimated to have been, on 
average, 2.21(±1.18)%, based on the amount of enzyme washed out of the polymer 
delivery formulation. Expressed as a percentage these values appear low due to the 
high amount of total protein added to the system (150mg).  However, they are 
comparable to similar examples within the current literature.  The average amount of 
protein encapsulated is 22.1g per 1mg poly(glycol adipate-co--pentadecalactone), 
which is comparable to that reported by Perez-Rodriguez et al. (2003): 16.7g 
chymotrypsin encapsulated per 1mg PLGA polymer.  There are considerable 
differences in the encapsulation efficiencies of the 3 separate batches prepared 
possibly reflecting the variation in the encapsulation procedure and errors inferred 
during measurement of washed-out protein in the presence of higher PVA
concentrations. Nonetheless, they are exemplary of the results possible from such 
systems and are represented here as a ‘proof-of-principle’ concept. 
The temporal chymotrypsin release samples collected were analysed for total 
protein content via the UV absorbance assay, see figure 3.  From the release data it 
was observed that maximal release was achieved upon 2h incubation.  
[Insert FIGURE 3 about here]
The average maximal release concentrations for all batches of particles from 2h 
onwards were further used to calculate the total amount of protein releasable from the 
particles, see table 2.  The calculated amounts of enzyme encapsulated for the 3 
batches, table 1, were supported by the estimated amount of enzyme subsequently 
released from the particles, shown in table 2.  These were further expressed as 
encapsulation yields, using equation (3) and enzyme load, using equation (2) above.
                  
_ ( )
. (%) 100
_ _ ( )
Protein released mg
Encap Yield x
Protein amount added mg
                     (3)
[Insert TABLE 2 about here]
The encapsulation efficiencies in table 1 were calculated by measurement of the 
non-encapsulated protein present in the wash samples and are based on the 
assumption that there is no protein loss during the preparation and processing of 
particles.  Also, due to the influence higher concentrations of PVA can have on the 
UV protein concentration measurements, an overestimation of the non-encapsulated 
enzyme was predicted. Thus, an underestimation of the encapsulation efficiencies 
may have occurred.
The encapsulation efficiency and yield are based on different presumptions; the 
former centring on how much is not present in the samples and the latter how much is. 
Nonetheless, only with the D2 particles (multiple emulsion particles-batch 2) did they 
differ significantly at p=0.05 confidence level (encapsulation efficiency 10.31% and 
encapsulation yield 6.48%). This lead to the presumption that most of the 
chymotrypsin encapsulated was released.  Loss of protein due to non-specific
adsorption to the surface may be accountable for the minimal discrepancies in the 
values obtained and were not quantified in this study.  The possibility of a second 
phase of enzyme release that would coincide with particle/copolymer degradation 
should not be neglected.  Monitoring the release of protein over longer periods of time 
may reveal more information on this. No protein release was observed from the 
control single emulsion particles, thus it was concluded that all the surface-adsorbed 
protein was removed during the wash step.  The absorbance readings taken at 282nm 
for these release samples were of a negligible negative value (ranging from -0.0650 to 
–0.0887 A.U.), thus confirmed no hindrance of protein UV absorbance measurement 
from other components used in the preparation of the particles.  
The physiological activity of the released chymotrypsin was estimated via the 
active site titration (MUTMAC) assay.  This fluorescent based assay revealed a
decrease in amount of active sites over time.  Maximal activity was observed upon 1h.  
Assessing the proteolytic activity of the released chymotrypsin via the colorimetric 
azocasein assay revealed a similar activity profile, with an onset of loss of proteolysis 
upon 2h release (figure 4).  This confirms the above active site titration results.
[Insert FIGURE 4 about here]
These two assays were used to measure the amount of active enzyme released 
from particles prepared from multiple emulsions.  The fluorescent MUTMAC assay is 
based on the irreversible binding of an -chymotrypsin substrate, (N,N,N-
trimethylammonium)cinnamate, and subsequent release of the fluorophore 4-
methylumbelliferone. This results in a direct correlation between active sites present 
and fluorescent intensity. The azocasein assay is based on the release of 
sulfanilamide covalently linked to casein upon proteolytic digestion of this generic 
substrate.  The released sulfanilamide is measured spectrophotometrically and reflects 
the proteolytic activity of the sample.  Both techniques revealed a reduction in 
activity, implying that some form of conformational change to the active site of 
chymotrypsin had occurred. 
Control experiments were set where 1mg mL-1 chymotrypsin in PBS was 
incubated at 37oC and 100rpm for 5.5h.  No detrimental effect on chymotrypsin 
activity was observed.  Hence it was concluded that the enzyme released from 
particles did not loose its activity due to the incubation conditions but during the 
emulsification process.  Perez-Rodriguez et al. (2003) reported the detrimental effect 
the dichloromethane/water interface has on chymotrypsin inactivation and 
aggregation during the process of encapsulation into PLGA particles, suggesting a 
combination of suitable excipients may reduce the observed protein unfolding.  
Furthermore, Castellanos et al. (2002) address the effects of various physical and 
chemical parameters on the integrity and activity of encapsulated -chymotrypsin.  
They observed an increased level of aggregation and loss of activity upon release of 
the enzyme when encapsulated via the solid-in-oil-in-water (s/o/w) technique.  
However, they do demonstrate the beneficial effects of co-lyophilising the enzyme 
with poly(ethylene-glycol) (PEG) prior to encapsulation suggesting this as a potential 
preventative measure.  Similarly, a decrease in enzyme activity was also observed by 
Gaspar et al (1998) when they encapsulated L-asparaginase in PLGA nanoparticles. 
They monitored the release and activity of L-asparaginase and noted a decline in 
activity upon 2 or 7 days, depending on the polymer molecular weight. Contrary to 
above literature, their investigation into whether the particle preparation process 
damages the enzyme resulted in negative results and the authors concluded no 
aggregation or cleavage of the protein occurs during the emulsification steps of 
particle preparation.  Nonetheless, upon longer release studies (3 weeks), some 
physical alteration of the released L-asparaginase was observed with SDS-PAGE, 
leading to the assumption that the enzyme may undergo denaturation once released 
from the colloidal systems.  The decline in activity in the current work occurred much 
sooner than that reported in the literature, with a gradual decrease in activity observed 
after 2h release; refer to figure 4.
The influence of polymer molecular weight on protein encapsulation has been 
previously addressed with higher molecular weights polymers producing particles 
with slower release rates than lower molecular weight polymers (Gaspar et al., 1998; 
Song et al., 1997).  Thus, simply altering the molecular weight of poly(glycerol 
adipate-co--pentadecalactone) would afford adjustments in size range and 
performance of the colloidal delivery system.  Research into the effect different 
physical properties of the functional copolymers may have on protein encapsulation 
could reveal a more efficient system. Additionally, further aspects of optimisation of 
such a delivery system may address the issue of the enzyme activity.  Lyoprotectants 
have been used to decrease the adverse effects freeze-drying has on proteins (Gupta 
and Roy, 2004).  Various other additives to the system have been shown to improve 
the encapsulation and subsequent release of hydrophilic compounds.  Addition of salt 
to the outer aqueous phase decreases the proportion of partitioned protein by 
depressing its aqueous solubility (Dinarvand et al., 2005).  Alternatively, spray drying 
has been effectively used to encapsulate insulin in PLGA microparticles with reported 
minimal denaturation of the protein upon release (Quiglia et al., 2003). 
Future aspects of the optimisation of the poly(glycerol adipate-co--
pentadecalactone)/protein delivery system may also include assessment of various 
excipients to improve delivery and activity of the therapeutic enzyme in addition to 
evaluating the colloidal system capacity for different protein targets. Degradation 
profiles of the polymer formulation and its effects on the delivery of drugs should be 
further investigated.
Conclusions
These initial investigations of utilising functional enzyme-synthesised polyesters for 
delivery of proteins via microparticles indicate the potential for future development of 
such systems. Within the poly(glycol adipate-co--pentadecalactone) colloidal 
system 22.1g protein was encapsulated per 1mg polymer.  Release of this protein 
from the particles was observed over 7h and a continuous loss of enzyme activity was 
recorded during this time period.  Altering the chemistry of the polymer backbone,
attaching functional moieties, or drugs and/or protein, to the polymer would offer a 
variety of physical characteristics required to improve the delivery vehicle and enable 
combined delivery of both hydrophobic drug and hydrophilic enzyme.  Modifications 
to the emulsion-solvent evaporation procedure may afford ameliorated enzyme 
activity upon release, providing a more suitable system for delivery of pharmaceutical 
proteins.
Previous studies have been performed on biocompatibility of the commonly used 
polyesters for various applications (Vaquette et al., 2006).  Kallinteri et al. (2005)
investigated the cytotoxicity of microspheres of poly(glycol adipate) and acylated 
derivatives of this polymer designed for parenteral delivery. They concluded low 
toxicity of their delivery systems. Given the nature of the copolymers used in this 
study it is anticipated that they will exhibit similar biocompatibility to the individual
PGA and polylactones and this is currently under investigation.
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Table 1. Encapsulation efficiencies of -chymotrypsin within the particles 
formulated over 3h via the multiple emulsion solvent evaporation technique. Separate 
batches of enzyme containing particles were prepared: D1, D2 and D3. The amount 
of -chymotrypsin added into the emulsion was 150mg (1.5mL of 100mg mL-1). The 
-chymotrypsin (CT) concentration in the washes was determined via the UV 
absorbance assay.  The amount of -chymotrypsin encapsulated was determined as 
the amount added minus the amount washed out.
Batch Sample
Amount 
of CT
washed 
out (mg)
Total CT
amount
washed 
out (mg)
Encap.
amount
of CT
(mg)
Encap. 
efficiency 
(%)
Enzyme 
load 
(%)*
D1 wash 1
wash 2
133.67
6.47 140.14 9.86 6.58 2.19
D2 wash 1
wash 2
126.59
8.11 134.69 15.31 10.21 3.40
D3 wash 1
wash 2
136.66
8.69 145.35 4.65 3.10 1.03
* per 450mg polymer 
Table 2.  Encapsulation yield of -chymotrypsin within double emulsion particles 
calculated as the total amount of protein releasable from the system under the given 
conditions.  The maximal release concentration of -chymotrypsin (CT) was 
determined from the release profile, figure 2, as the average concentration of both sets 
of results from 2h to 5.5h incubation for each batch of particles.  The amount of -
chymotrypsin added into the particle preparation emulsions was 150mg (1.5mL of 
100mg mL-1).
Batch
Average max. release 
of CT (±st.deviation) 
(mg mL-1)
Amount of 
CT released*
(mg)
Encapsulation 
yield (%)
Enzyme 
load 
(%)*
D1 0.207 (±0.024) 9.32 6.21 2.07
D2 0.216 (±0.026) 9.73 6.48 2.16
D3 0.145 (±0.028) 6.53 4.36 1.45
* per 450mg polymer
Figure legends
Figure 1.  Diffusion of -chymotrypsin from the internal aqueous phase of a multiple 
emulsion.  The concentration of protein in the outer aqueous phase was measured 
using the UV absorbance assay.  The dichloromethane evaporated from the double 
emulsion system within 2.5h, indicated by the arrow.  Four replicate systems of the 
double emulsions were prepared (Double 1-4).  The three single emulsion systems 
were monitored as controls (Single 1-3).  The results are represented as means of 3 
separate readings of the samples, and standard deviations are shown.
Figure 2.  Scanning electron microscope images of particles formed by the multiple 
emulsion solvent evaporation technique.  Image A) was taken at x1000 magnification 
and the scale bar represents 30m, whereas image B) x3000 rpm and the scale bar 
represents 10m.
Figure 3.  Release profiles of -chymotrypsin from particles formed over 3h by the 
multiple emulsion solvent evaporation methodology.  Three batches were assessed: 
D1, D2 and D3.  Duplicate samples were obtained for each time point from each 
batch.  The results are expressed as means of 3 separate measurements of the samples, 
with the average standard deviation being 0.02861±0.0008 and represented only on 
the D3 run 2 5h point for clarity of graph.
Figure 4.  Activity of released enzyme compared to total protein.  Proteolytic activity 
of the samples was determined via the azocasein assay and compared to a -
chymotrypsin standard curve.  Total protein content was assessed using UV 
absorbance at 282nm assay and comparing with a -chymotrypsin standard curve. 
Release profile repeated in triplicate with 3 measurements made for each sample. 
Results represented as mean±standard deviation.
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